mdna11
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 27, 2021 (NCT05086692)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Basal Cell Carcinoma · Phase 1/Phase 2
- Biliary Tract Neoplasms · Phase 1/Phase 2
- Carcinoma, Hepatocellular · Phase 1/Phase 2
- Carcinoma, Merkel Cell · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Carcinoma, Ovarian Epithelial · Phase 1/Phase 2
- Carcinoma, Renal Cell · Phase 1/Phase 2
- Carcinoma, Squamous Cell · Phase 1/Phase 2
- Cholangiocarcinoma · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Endometrial Neoplasms · Phase 1/Phase 2
- Esophageal Neoplasms · Phase 1/Phase 2
- Fallopian Tube Neoplasms · Phase 1/Phase 2
- Gallbladder Neoplasms · Phase 1/Phase 2
- Hamartoma · Phase 1/Phase 2
- Melanoma · Phase 1/Phase 2
- Mesothelioma · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 1/Phase 2
- Pancreatic Neoplasms · Phase 1/Phase 2
- Sarcoma · Phase 1/Phase 2
- Skin Neoplasms · Phase 1/Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 1/Phase 2
- Stomach Neoplasms · Phase 1/Phase 2
- Triple Negative Breast Neoplasms · Phase 1/Phase 2
- Urinary Bladder Neoplasms · Phase 1/Phase 2
- Uterine Cervical Neoplasms · Phase 1/Phase 2
- Uterine Neoplasms · Phase 1/Phase 2
Mechanism of action
- Interleukin-2Supplementation
IL2 supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05086692 | Phase 1/Phase 2 (Phase 2) | Aug 27, 2021 | Medicenna Therapeutics, Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Medicenna Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2021 |
1 organizations
Page 1 / 1